Business Context and Reporting Period
Company: Rockwell Medical, Inc. (RMTI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Rockwell Medical develops, manufactures, and distributes hemodialysis products, primarily liquid and dry acid/bicarbonate concentrates, to dialysis providers in the U.S. and internationally. The Company operates in a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Net Sales | $17,780 | $35,116 | $34,985 |
| Gross Profit | $3,243 | $6,140 | $5,545 |
| Gross Margin | 18.2% | 17.5% | 15.9% |
| Operating Loss | $(1,061) | $(2,541) | $(2,709) |
| Net Loss | $(1,172) | $(2,777) | $(3,007) |
| Diluted Net Loss Per Share | $(0.34) | $(0.74) | $(0.92) |
| Cash & Cash Equivalents | $10,519 (as of June 30, 2026) | ||
| Investments (Available-for-Sale) | $14,278 (as of June 30, 2026) | ||
| Total Liquidity | $24.8 million | ||
| Working Capital | $25.2 million | ||
| Term Loans (Outstanding) | $9.0 million (net of issuance costs) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year for the quarter ($17.8M vs. $16.1M) and remained flat for the six-month period ($35.1M vs. $35.0M). The six-month flatline was driven by a $4.3M reduction in sales to DaVita, offset by $2.7M in new customer sales (Western U.S.) and price increases.
- Margin Expansion: Gross margin improved to 18.2% in Q2 2026 from 16% in Q2 2025. This was driven by lower manufacturing costs due to reduced production headcount and overhead, partially offset by the loss of a one-time price adjustment revenue from DaVita in the prior year.
- Operating Efficiency: Operating loss narrowed by 21% in Q2 and 6% in the six-month period compared to 2025. Selling and marketing expenses decreased 11% year-over-year for the six months due to lower headcount.
- Customer Concentration: DaVita's contribution to net sales dropped significantly from 20% in the first half of 2025 to 7% in the first half of 2026, following a contract extension that included a transition period.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current working capital ($25.2M) and cash resources ($24.8M) are sufficient to meet operating requirements for at least the next 12 months. The Company has $13.1M remaining availability under its At-The-Market (ATM) equity facility.
- Debt Covenants: The Company is in compliance with all covenants under its Loan Agreement with Innovatus. The agreement includes an interest-only period for 36 months, with principal payments beginning February 1, 2027, and maturity on January 1, 2029.
- Strategic Focus: The Company is focused on cost containment, expanding revenue with new customers, and securing pricing with existing accounts to achieve sustainable profitability.
- Risks: Key risks include the global macroeconomic environment, supply chain weaknesses, and the potential inability to raise additional capital on favorable terms. The Company also faces risks related to customer concentration and contract disputes.
- Subsequent Event: On July 1, 2026, the Company effected a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. All share and per-share data in this filing have been retrospectively adjusted.
Investor Verification Checklist
- DaVita Contract Status: Verify the long-term impact of the DaVita transition and the sustainability of the new pricing structure under the "Second Extension Term" through December 2026.
- Cash Burn vs. Runway: Confirm the trajectory of operating cash flow ($1.9M provided in H1 2026) against the $9.0M term loan principal payments due starting in 2027.
- Reverse Stock Split Impact: Monitor post-split trading volume and price stability to ensure continued compliance with Nasdaq listing rules.
- Customer Diversification: Assess the success of acquiring new customers in the Western U.S. to offset the loss of DaVita volume.
- Debt Refinancing: Evaluate the terms and availability of refinancing options prior to the 2027 principal payment commencement, given the current interest rate environment.